Tools
Tools
Ritchie, L, Qin, S, Penson, P, Henney, N and Lip, G (2020) Vernakalant hydrochloride for the treatment of atrial fibrillation: An evaluation of its place in clinical practice. Future Cardiology, 16 (6). pp. 585-595. ISSN 1479-6678
|
Text
Revised Vernakalant without tracked changes (003).pdf - Accepted Version Download (732kB) | Preview |
Abstract
Vernakalant is an intravenous anti-arrhythmic drug available in Europe, Canada and some countries in Asia for the restoration of sinus rhythm in acute onset atrial fibrillation. Currently, it is not available in the United States because the Food and Drug Administration have ongoing concerns about its safety. Vernakalant has a unique pharmacological profile of multi-ion channel activity and atrial-specificity that distinguishes it from other anti-arrhythmic drugs. This is thought to enhance efficacy but there are concerns of adverse events stemming from its diverse pharmacology. This ambiguity has prompted a review of the available clinical evidence on efficacy and safety to help re-evaluate its place in clinical practice.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | 1102 Cardiorespiratory Medicine and Haematology |
| Subjects: | R Medicine > RM Therapeutics. Pharmacology |
| Divisions: | Pharmacy & Biomolecular Sciences |
| Publisher: | Future Medicine |
| Date Deposited: | 01 May 2020 08:37 |
| Last Modified: | 12 Jan 2022 16:30 |
| DOI or ID number: | 10.2217/fca-2020-0039 |
| URI: | https://researchonline.ljmu.ac.uk/id/eprint/12861 |
 |
View Item |